drugset / Trial / NCT00003339
Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma
Phase 2
Completed
48 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
RandomizedTreatment
Summary
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response that will kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood cells to kill melanoma cells. PURPOSE: Randomized phase II trial to determine the effectiveness of vaccine therapy given with interleukin-12 in treating patients who have stage III or stage IV melanoma.
Timeline
- Start
- 1998-11
- Primary completion
- 1999-11
- Completion
- 2004-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gp100 antigen | Peptide | — | Subcutaneous |
| Subject | interleukin-12 | Protein / enzyme biologic | — | Subcutaneous |
| Subject | tyrosinase peptide | Peptide | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |